Hualan Biological EngineeringInc (SHE:002007) — Market Cap & Net Worth

$3.86 Billion USD  · CN¥26.35 Billion CNY  · Rank #4238

Market Cap & Net Worth: Hualan Biological EngineeringInc (002007)

Hualan Biological EngineeringInc (SHE:002007) has a market capitalization of $3.86 Billion (CN¥26.35 Billion) as of May 4, 2026. Listed on the SHE stock exchange, this China-based company holds position #4238 globally and #740 in its home market, demonstrating a -3.16% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hualan Biological EngineeringInc's stock price CN¥14.42 by its total outstanding shares 1827456666 (1.83 Billion). Analyse Hualan Biological EngineeringInc (002007) cash conversion ratio to see how efficiently the company converts income to cash.

Hualan Biological EngineeringInc Market Cap History: 2015 to 2026

Hualan Biological EngineeringInc's market capitalization history from 2015 to 2026. Data shows growth from $3.42 Billion to $3.86 Billion (2.14% CAGR).

Index Memberships

Hualan Biological EngineeringInc is a constituent of 1 market index:

Index Total Market Cap Weight (%) Rank by Market Cap
Shanghai Shenzhen CSI 300
CSI300
$4.18 Trillion 0.09% #162 of 285

Weight: Hualan Biological EngineeringInc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Hualan Biological EngineeringInc Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Hualan Biological EngineeringInc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

1.03x

Hualan Biological EngineeringInc's market cap is 1.03 times its annual revenue

Industry average: 3784.39x Lower than industry average

Latest Price to Earnings (P/E) Ratio

4.14x

Hualan Biological EngineeringInc's market cap is 4.14 times its annual earnings

Industry average: 0.19x Higher than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2015 $3.42 Billion $1.47 Billion $589.12 Million 2.32x 5.81x
2016 $4.48 Billion $1.93 Billion $780.31 Million 2.32x 5.74x
2017 $3.41 Billion $2.37 Billion $820.82 Million 1.44x 4.15x
2018 $4.20 Billion $3.22 Billion $1.14 Billion 1.30x 3.68x
2019 $6.81 Billion $3.70 Billion $1.28 Billion 1.84x 5.31x
2020 $10.75 Billion $5.02 Billion $1.61 Billion 2.14x 6.67x
2021 $7.48 Billion $4.44 Billion $1.30 Billion 1.69x 5.76x
2022 $5.87 Billion $4.52 Billion $1.08 Billion 1.30x 5.45x
2023 $5.82 Billion $5.34 Billion $1.48 Billion 1.09x 3.93x
2024 $4.51 Billion $4.38 Billion $1.09 Billion 1.03x 4.14x

Competitor Companies of 002007 by Market Capitalization

Companies near Hualan Biological EngineeringInc in the global market cap rankings as of May 4, 2026.

Key companies related to Hualan Biological EngineeringInc by market ranking:

  • Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
  • Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
  • UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
  • argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#223 Vertex Pharmaceuticals Inc NASDAQ:VRTX $107.56 Billion $423.92
#367 Regeneron Pharmaceuticals Inc NASDAQ:REGN $72.88 Billion $701.42
#517 UCB SA BR:UCB $51.45 Billion €231.20
#568 argenx NV ADR NASDAQ:ARGX $45.97 Billion $787.95

Hualan Biological EngineeringInc Historical Marketcap From 2015 to 2026

Between 2015 and today, Hualan Biological EngineeringInc's market cap moved from $3.42 Billion to $ 3.86 Billion, with a yearly change of 2.14%.

Year Market Cap Change (%)
2026 CN¥3.86 Billion -4.69%
2025 CN¥4.05 Billion -10.21%
2024 CN¥4.51 Billion -22.52%
2023 CN¥5.82 Billion -0.87%
2022 CN¥5.87 Billion -21.57%
2021 CN¥7.48 Billion -30.45%
2020 CN¥10.75 Billion +57.89%
2019 CN¥6.81 Billion +62.30%
2018 CN¥4.20 Billion +23.17%
2017 CN¥3.41 Billion -23.98%
2016 CN¥4.48 Billion +31.04%
2015 CN¥3.42 Billion --

End of Day Market Cap According to Different Sources

On May 3rd, 2026 the market cap of Hualan Biological EngineeringInc was reported to be:

Source Market Cap
Yahoo Finance $3.86 Billion USD
MoneyControl $3.86 Billion USD
MarketWatch $3.86 Billion USD
marketcap.company $3.86 Billion USD
Reuters $3.86 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Hualan Biological EngineeringInc

SHE:002007 China Biotechnology
Market Cap
$3.86 Billion
CN¥26.35 Billion CNY
Market Cap Rank
#4238 Global
#740 in China
Share Price
CN¥14.42
Change (1 day)
-0.83%
52-Week Range
CN¥14.20 - CN¥17.72
All Time High
CN¥235131.81
About

Hualan Biological Engineering Inc. researches, develops, produces, and commercializes blood products, vaccines, and genetic engineering products in China and internationally. The company offers human serum albumin to treat blood loss trauma, shock caused by burns, intracranial pressure and persistent, liver cirrhosis, and kidney disease; edema for hypoproteinemia, neonatal hyperbilirubinemia, car… Read more